These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 31870827)

  • 1. Pancreatitis and pancreatic cancer in patientes treated with Dipeptidyl Peptidase-4 inhibitors: An extensive and updated meta-analysis of randomized controlled trials.
    Dicembrini I; Montereggi C; Nreu B; Mannucci E; Monami M
    Diabetes Res Clin Pract; 2020 Jan; 159():107981. PubMed ID: 31870827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of cancer in patients treated with dipeptidyl peptidase-4 inhibitors: an extensive meta-analysis of randomized controlled trials.
    Dicembrini I; Nreu B; Montereggi C; Mannucci E; Monami M
    Acta Diabetol; 2020 Jun; 57(6):689-696. PubMed ID: 31955260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular events and all-cause mortality in patients with type 2 diabetes treated with dipeptidyl peptidase-4 inhibitors: An extensive meta-analysis of randomized controlled trials.
    Mannucci E; Nreu B; Montereggi C; Ragghianti B; Gallo M; Giaccari A; Monami M;
    Nutr Metab Cardiovasc Dis; 2021 Sep; 31(10):2745-2755. PubMed ID: 34364771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bullous pemphigoid and dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized controlled trials.
    Silverii GA; Dicembrini I; Nreu B; Montereggi C; Mannucci E; Monami M
    Endocrine; 2020 Sep; 69(3):504-507. PubMed ID: 32236820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials.
    Monami M; Dicembrini I; Mannucci E
    Diabetes Obes Metab; 2014 Jan; 16(1):48-56. PubMed ID: 23837679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials.
    Monami M; Dicembrini I; Mannucci E
    Nutr Metab Cardiovasc Dis; 2014 Jul; 24(7):689-97. PubMed ID: 24793580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials.
    Monami M; Dicembrini I; Martelli D; Mannucci E
    Curr Med Res Opin; 2011 Nov; 27 Suppl 3():57-64. PubMed ID: 22106978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of dipeptidyl peptidase-4 inhibitors on serum adiponectin: a meta-analysis.
    Liu X; Men P; Wang Y; Zhai S; Liu G
    Lipids Health Dis; 2016 Nov; 15(1):204. PubMed ID: 27881129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do dipeptidyl peptidase IV (DPP-IV) inhibitors cause heart failure?
    Clifton P
    Clin Ther; 2014 Dec; 36(12):2072-2079. PubMed ID: 25453730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in baseline characteristics between type 2 diabetes mellitus patients treated with dipeptidyl peptidase-4 inhibitors in randomized controlled trials and those receiving the same treatment in real-world settings
.
    Kostev K; Schokker E; Jacob L
    Int J Clin Pharmacol Ther; 2018 Sep; 56(9):411-416. PubMed ID: 30049306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of dipeptidyl peptidase-4 inhibitors on bone fracture among patients with type 2 diabetes mellitus: A network meta-analysis of randomized controlled trials.
    Yang J; Huang C; Wu S; Xu Y; Cai T; Chai S; Yang Z; Sun F; Zhan S
    PLoS One; 2017; 12(12):e0187537. PubMed ID: 29206832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of pancreatitis and pancreatic cancer in a randomized controlled multicenter trial (SAVOR-TIMI 53) of the dipeptidyl peptidase-4 inhibitor saxagliptin.
    Raz I; Bhatt DL; Hirshberg B; Mosenzon O; Scirica BM; Umez-Eronini A; Im K; Stahre C; Buskila A; Iqbal N; Greenberger N; Lerch MM
    Diabetes Care; 2014 Sep; 37(9):2435-41. PubMed ID: 24914244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of dipeptidyl peptidase-4 inhibitors on circulating tumor necrosis factor-α concentrations: A systematic review and meta-analysis of controlled trials.
    Atkin SL; Katsiki N; Banach M; Mikhailidis DP; Pirro M; Sahebkar A
    J Diabetes Complications; 2017 Sep; 31(9):1458-1464. PubMed ID: 28647512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies.
    Li L; Shen J; Bala MM; Busse JW; Ebrahim S; Vandvik PO; Rios LP; Malaga G; Wong E; Sohani Z; Guyatt GH; Sun X
    BMJ; 2014 Apr; 348():g2366. PubMed ID: 24736555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gastrointestinal Adverse Events of Dipeptidyl Peptidase 4 Inhibitors in Type 2 Diabetes: A Systematic Review and Network Meta-analysis.
    Wu S; Chai S; Yang J; Cai T; Xu Y; Yang Z; Zhang Y; Ji L; Sun F; Zhan S
    Clin Ther; 2017 Sep; 39(9):1780-1789.e33. PubMed ID: 28827024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis.
    Gooßen K; Gräber S
    Diabetes Obes Metab; 2012 Dec; 14(12):1061-72. PubMed ID: 22519906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The safety of gliptins : updated data in 2018.
    Scheen AJ
    Expert Opin Drug Saf; 2018 Apr; 17(4):387-405. PubMed ID: 29468916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis.
    Scheen A
    Expert Opin Drug Saf; 2013 Jul; 12(4):545-57. PubMed ID: 23621381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardioprotective effects of dipeptidyl peptidase-4 inhibitors versus sulfonylureas in addition to metformin: A nationwide cohort study of patients with type 2 diabetes.
    Wang J; Wu HY; Chien KL
    Diabetes Metab; 2022 May; 48(3):101299. PubMed ID: 34728339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
    Scirica BM; Bhatt DL; Braunwald E; Steg PG; Davidson J; Hirshberg B; Ohman P; Frederich R; Wiviott SD; Hoffman EB; Cavender MA; Udell JA; Desai NR; Mosenzon O; McGuire DK; Ray KK; Leiter LA; Raz I;
    N Engl J Med; 2013 Oct; 369(14):1317-26. PubMed ID: 23992601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.